---

---

source : Www.biospace.com   

save search

---

Top 5 Remote Regulatory Jobs
Published: 2024-04-25 (Crawled : 06:00) - biospace.com/
LLY | News | $732.2 -1.81% -0.84% 1.7M |

Health Technology

| Email alert Add to watchlist

---

Why Biopharma Companies Avoid Hiring People Who Need Visas
Published: 2024-04-25 (Crawled : 05:00) - biospace.com/
JNJ | News | $148.53 -0.69% 0.18% 7.5M |

Health Technology

| Email alert Add to watchlist
companies avoid biopharma

---

BioMarin Reports Record Financial Results for the First Quarter 2024
Published: 2024-04-24 (Crawled : 00:00) - biospace.com/
BMRN | $91.2 -0.93% -0.89% 550 |

Health Technology

| 0.08% | O: 0.08% H: 0.0% C: 0.0%
first for financial results

---

Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Second Quarter Results
Published: 2024-04-24 (Crawled : 23:00) - biospace.com/
ARWR | $23.29 -2.06% -2.13% 810K |

Health Technology

| -2.06% | O: -0.17% H: 0.08% C: -1.9%
pharmaceuticals results

---

Pulse Biosciences Schedules First Quarter 2024 Financial Results Conference Call for May 7, 2024
Published: 2024-04-24 (Crawled : 22:00) - biospace.com/
PLSE | $6.86 0.0% 130K |

Health Technology

| 0.0% | O: 0.87% H: 0.14% C: -0.87%
first conference for financial results

---

Arcus Biosciences to Present New Data from Phase 2 Studies of Novel Immuno-Oncology Combinations at the 2024 ASCO Annual Meeting
Published: 2024-04-24 (Crawled : 22:00) - biospace.com/
RCUS 4 | $15.43 -0.45% 0.0% 520K |

Health Technology

| -0.45% | O: -0.06% H: 2.32% C: -0.39%
asco arcus meeting

---

Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024
Published: 2024-04-24 (Crawled : 21:00) - biospace.com/
ACAD | News | $16.59 -0.9% -1.03% 1.3M |

Health Technology

| -0.9% | O: 0.42% H: 0.3% C: -1.31%
first pharmaceuticals financial results

---

Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting
Published: 2024-04-24 (Crawled : 19:00) - biospace.com/
PGEN | $1.42 1.43% 1.41% 570K |

Health Technology

| 1.43% | O: 0.0% H: 2.14% C: 1.43%
prgn-2012 respiratory asco treatment immunotherapy for meeting study

---

Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024
Published: 2024-04-24 (Crawled : 19:00) - biospace.com/
NVCR | $12.34 2.36% 2.39% 1.3M |

Health Technology

| 2.41% | O: 0.33% H: 2.48% C: 2.07%
lung asco cancer cell for trial results

---

NanoVibronix to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024
Published: 2024-04-24 (Crawled : 18:00) - biospace.com/
NAOV 4 | $0.75 -2.6% -5.68% 8.7K |

Health Technology

| -2.6% | O: -1.3% H: 1.32% C: -1.32%
microcap

---

First Approval for Rare Pediatric Cancer; New OTC Opioid Overdose Option
Published: 2024-04-24 (Crawled : 16:00) - biospace.com/
SNYNF | News | $94.0 -0.27% -2.18% 310 |

Health Technology

| -0.27% | O: 0.8% H: 0.0% C: -1.05%
PRGO | $31.23 2.43% 0.0% 960K |

Health Technology

| 2.43% | O: 0.1% H: 0.0% C: 0.0%
JNJ | News | $148.53 -0.69% 0.18% 7.5M |

Health Technology

| -1.02% | O: -1.02% H: 0.0% C: 0.0%
ABT | News | $106.89 -0.65% -0.09% 4.2M |

Health Technology

| -0.65% | O: -0.82% H: 0.37% C: 0.17%
XOMA | $25.64 -1.73% -3.9% 8.2K |

Health Technology

| -1.72% | O: 0.19% H: 0.0% C: -1.91%
SNY | News | $46.61 -2.27% -2.21% 1.6M |

Health Technology

| 0.82% | O: 0.82% H: 0.0% C: 0.0%
rare first opioid approval for

---

CureVac Appoints Thaminda Ramanayake as New Chief Business Officer
Published: 2024-04-24 (Crawled : 15:00) - biospace.com/
SNYNF | News | $94.0 -0.27% -2.18% 310 |

Health Technology

| -0.27% | O: 0.8% H: 0.0% C: -1.05%
JNJ | News | $148.53 -0.69% 0.18% 7.5M |

Health Technology

| -1.02% | O: -1.02% H: 0.0% C: 0.0%
SNY | News | $46.61 -2.27% -2.21% 1.6M |

Health Technology

| 0.82% | O: 0.82% H: 0.0% C: 0.0%
CVAC | $2.51 -3.46% -3.59% 1.3K |

Health Technology

| -3.46% | O: -4.62% H: 4.44% C: 1.21%
business

---

BioStem Technologies Inc. Completes Two-Year Audit, Prepares for Uplisting to Senior ExchangeStrategic Audit Completion Set to Enhance BioStem Technologies' Market Position and Shareholder Value
Published: 2024-04-24 (Crawled : 15:00) - biospace.com/
BSEM | $9.355 1.24% -38.71% 0 |

n/a

| 1.3% | O: 0.0% H: 1.73% C: 1.3%
for set market

---

Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing
Published: 2024-04-24 (Crawled : 14:00) - biospace.com/
SNPX | $4.56 -0.22% 0.65% 14K |

Professional, Scientific, and T...

| -0.22% | O: 0.22% H: 2.4% C: -0.44%
nasdaq for

---

Lantern Pharma Launches “Webinar Wednesdays” Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development
Published: 2024-04-24 (Crawled : 14:00) - biospace.com/
SNYNF | News | $94.0 -0.27% -2.18% 310 |

Health Technology

| -0.27% | O: 0.8% H: 0.0% C: -1.05%
SNY | News | $46.61 -2.27% -2.21% 1.6M |

Health Technology

| 0.82% | O: 0.82% H: 0.0% C: 0.0%
LTRN | News | $5.38 -6.76% -6.07% 98K |

Health Technology

| -6.76% | O: 1.21% H: 2.91% C: -7.88%
pharma drug key leaders development

---

GoodRx Announces Date for 2024 Investor Day
Published: 2024-04-24 (Crawled : 14:00) - biospace.com/
GDRX 4 | $6.96 -0.14% -0.14% 20 |

Technology Services

| 4.66% | O: 5.64% H: 0.0% C: 0.0%
day for

---

United Therapeutics Announces World’s First Successful Xenothymokidney Transplant
Published: 2024-04-24 (Crawled : 14:00) - biospace.com/
UTHR | $237.0 1.08% 1.09% 670K |

Health Technology

| 0.88% | O: -0.56% H: 3.16% C: 1.45%
first therapeutics

---

Kiromic BioPharma Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients
Published: 2024-04-24 (Crawled : 14:00) - biospace.com/
KRBP | $2.71 2.65% -90.21% 1.6K |

Health Technology

| 2.65% | O: 0.0% H: 11.74% C: 2.65%
first favorable biopharma trial

---

Neurocrine Biosciences Launches WHAT THE C@H?! Educational Initiative to Support Congenital Adrenal Hyperplasia Community
Published: 2024-04-24 (Crawled : 14:00) - biospace.com/
NBIX | News 4 | $138.97 -0.8% -0.85% 930K |

Health Technology

| -0.8% | O: 0.57% H: 2.7% C: -1.36%
initiative

---

CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK
Published: 2024-04-24 (Crawled : 14:00) - biospace.com/
CVAC | $2.51 -3.46% -3.59% 1.3K |

Health Technology

| -3.46% | O: -4.62% H: 4.44% C: 1.21%
start influenza collaboration development study

---

Gainers vs Losers

61%

39%

Top 10 Gainers

BOF | $2.08 77.78% 39.06% 110M |

BHIL | $0.1793 -4.37% 19.24% 340K |

Agriculture, Forestry, Fishing ...

UMAC | $1.48 -1.33% 14.87% 20K |

CI | $352.28 -0.11% 13.53% 2 |

Health Services

CIG.C | $2.89 -1.37% 12.8% 2.3K |

n/a

MTH | $154.69 -2.21% 12.68% 450K |

Consumer Durables

HCP | News | $31.41 7.75% 11.26% 1.2M |

BMTX 4 | $1.545 0.98% 10.03% 2.5K |

Information

TAL | $12.26 0.57% 9.22% 12M |

Consumer Services

ASXC | $0.243 -2.41% 7.0% 1.1M |

Manufacturing

---

Your saved searches

---